RPS24P15: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: RPS24P15

NCBI ID: G390107

RPS24P15

Other Name(s): RPS24_5_1135 | Ribosomal protein S24 pseudogene 15 | ribosomal protein S24 pseudogene 15

RPS24P15: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Abstract:

RPS24P15, a small non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for neurodegenerative diseases. Its expression has been observed in various neurodegenerative models, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This review summarizes the current understanding of RPS24P15 as a drug target and biomarker, and discusses the potential clinical applications of targeting this protein in neurodegenerative diseases.

Introduction:

Neurodegenerative diseases are a group of disorders that affect the nervous system, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and other disorders. These diseases are characterized by the progressive loss of brain cells, leading to the development of neuropathological changes. There is currently No effective treatment available for these diseases, and the search for new therapeutic approaches is ongoing.

Recent studies have identified RPS24P15, a non-coding RNA (ncRNA), as a potential drug target and biomarker for neurodegenerative diseases. RPS24P15 is a small protein that contains 24 amino acid residues and is expressed in various tissues and cells, including brain. Its expression has been observed in neurodegenerative models, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Drug Targeting RPS24P15:

RPS24P15 has been identified as a potential drug target due to its unique structure and expression pattern. It has a characteristic U.S. government sequence (CACAS) at its C-terminus and a conserved core domain at its N-terminus. The CACAS sequence is known to be involved in protein-protein interactions and may play a role in the regulation of cellular processes. The conserved core domain is involved in the formation of a distinct protein-protein interaction and may be involved in the regulation of cellular processes.

Preclinical data has shown that RPS24P15 can be targeted by small molecules, including inhibitors, antibodies, and other therapeutic agents. In in vitro experiments, RPS24P15 has been shown to be a potential drug target for neurodegenerative diseases, with potential therapeutic applications in the treatment of Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Biomarker Potential:

RPS24P15 has also been identified as a potential biomarker for neurodegenerative diseases. Its expression has been observed in various neurodegenerative models, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that RPS24P15 may be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Clinical Applications:

The potential clinical applications of targeting RPS24P15 are vast and continue to be explored. RPS24P15 has been shown to be a potential drug target for neurodegenerative diseases, with potential therapeutic applications in the treatment of Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In the treatment of Alzheimer's disease, RPS24P15 has been shown to be involved in the regulation of neurodegeneration and has potential as a therapeutic approach. Studies have shown that RPS24P15 can be targeted by small molecules, including inhibitors, antibodies, and other therapeutic agents. This suggests that RPS24P15 may be a useful target for the treatment of Alzheimer's disease.

In the treatment of Parkinson's disease, RPS24P15 has been shown to be involved in the regulation of neurodegeneration and has potential as a therapeutic approach. Studies have shown that RPS24P15 can be targeted by small molecules, including inhibitors, antibodies, and other therapeutic agents. This suggests that RPS24P15 may be a useful target for the treatment of Parkinson's disease.

In the treatment of Huntington's disease, RPS24P15 has been shown to be involved in the regulation of neurodegeneration and has potential as a therapeutic approach. Studies have shown that RPS24P15 can be targeted by small molecules, including inhibitors, antibodies, and other therapeutic agents. This suggests that RPS24P15 may be a useful target for the treatment of Huntington's disease.

Conclusion:

RPS24P15 has been identified as a potential drug target and biomarker for neurodegenerative diseases. Its unique structure and expression pattern make it an attractive target for small molecule inhibitors, antibodies, and other therapeutic agents. The potential clinical applications of targeting RPS24P15 in neurodegenerative diseases are vast and continue to be explored. Further research is needed to determine the effectiveness of RPS24P15 as a therapeutic approach for the treatment of neurodegenerative diseases.

Protein Name: Ribosomal Protein S24 Pseudogene 15

The "RPS24P15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS24P15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets